Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.
Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, Addison D, Baliga R, Stover DG, VanDeusen J, Williams N, Cherian M, Lustberg M, Wesolowski R, Ramaswamy B.
Sardesai S, et al. Among authors: stephens j.
Cardiooncology. 2020 Nov 5;6(1):26. doi: 10.1186/s40959-020-00081-9.
Cardiooncology. 2020.
PMID: 33292843
Free PMC article.